Periodic Benefit-Risk Evaluation Reports (PBRER)

The Periodic Benefit-Risk Evaluation Report (PBRER) is the ICH framework for periodic integrated evaluation of a medicinal product's worldwide benefit-risk profile. In the European Union, the legally established term remains Periodic Safety Update Report (PSUR), but the scientific structure and principles are aligned with ICH E2C(R2). The result is best understood as one scientific architecture implemented through region-specific legal procedures.

Purpose of Periodic Benefit-Risk Evaluation

A medicinal product's safety profile is incomplete at authorisation. Post-authorisation use expands exposure to larger, more heterogeneous populations and longer durations of treatment. New safety information, effectiveness evidence, regulatory actions and utilisation patterns can therefore alter the clinical interpretation of both benefits and risks.

The periodic report asks a broader question than "what adverse reactions occurred during the interval?" It asks:

What has changed in the evidence, and does that change the overall benefit-risk balance or require regulatory action?

This is why the PBRER is an analytical document rather than a compilation exercise.

Regulatory Framework

The scientific foundation is ICH E2C(R2). In the EU, the legal basis for PSURs is established in Directive 2001/83/EC, Regulation (EC) No 726/2004 and Commission Implementing Regulation (EU) No 520/2012. GVP Module VII — Periodic safety update report provides the detailed EU guidance on preparation, submission and assessment.

These sources should be distinguished:

• EU legislation establishes the obligation and procedural framework for PSURs.
• ICH E2C(R2) provides the internationally harmonised PBRER scientific structure.
• GVP Module VII explains EU implementation, including submission and assessment processes.
• EMA procedural guidance and the EURD list determine product- and substance-specific operational requirements.

PSUR Versus PBRER

The terms are related but not identical in origin.

A PBRER is the ICH scientific report format. A PSUR is the legal EU periodic-reporting instrument. In current EU practice, the PSUR follows the PBRER structure while complying with EU-specific procedural requirements.

This distinction matters because an organisation may prepare a globally harmonised PBRER core while still needing region-specific administrative adaptations.

The EURD List and Reporting Frequency

In the EU, many PSUR reporting schedules are harmonised through the European Union Reference Dates (EURD) list. The list can specify the Union reference date, data lock points and frequency for active substances or combinations.

MAHs should not assume that a historical product-specific schedule remains valid indefinitely. The applicable EURD entry, marketing-authorisation conditions and relevant regulatory decisions should be monitored.

The data lock point (DLP) is the cut-off for data included in the reporting interval. It is not the submission date. After the DLP, data validation, medical evaluation, writing, quality review and finalisation still occur.

PSUR Single Assessment

For active substances or combinations subject to a PSUR Single Assessment (PSUSA), the EU evaluates periodic reports in a coordinated procedure rather than as isolated product assessments. This supports harmonised conclusions across medicinal products containing the same active substance.

The outcome can lead to maintenance of the existing authorisation, requests for further information, product-information changes, risk-management changes or other regulatory action, depending on the assessment.

The PBRER Architecture

ICH E2C(R2) organises the report into a sequence that moves from product status and exposure, through interval safety information and signal evaluation, to cumulative risk assessment and integrated benefit-risk evaluation.

The principal sections are:

1. Introduction
2. Worldwide marketing-authorisation status
3. Actions taken in the reporting interval for safety reasons
4. Changes to reference safety information
5. Estimated exposure and patterns of use
6. Data in summary tabulations
7. Summaries of significant findings from clinical trials
8. Findings from non-interventional studies
9. Information from other clinical trials and sources
10. Non-clinical data
11. Literature
12. Other periodic reports
13. Lack of efficacy in controlled clinical trials
14. Late-breaking information
15. Overview of signals: new, ongoing or closed
16. Signal and risk evaluation
17. Benefit evaluation
18. Integrated benefit-risk analysis for authorised indications
19. Conclusions and actions
20. Appendices

The headings are not independent boxes. Sections 5–14 assemble and interpret evidence; Section 15 explains the signal landscape; Section 16 evaluates risks; Section 17 evaluates benefits; Section 18 integrates both sides of the balance; and Section 19 states what action follows.

For detailed section-by-section writing methodology, see [[how-to-write-a-pbrer]].

Interval Versus Cumulative Reasoning

A PBRER must distinguish what happened during the reporting interval from what is known cumulatively.

Interval data help identify change: new cases, studies, regulatory actions, signals or utilisation patterns. Cumulative data provide context: whether the interval information materially changes the established safety profile or benefit-risk understanding.

This is why a small number of interval cases can be important if they change the causal interpretation of a serious risk, while a large numerical increase may be unimportant if it merely reflects higher exposure without a change in rate or clinical pattern.

Exposure as the Denominator Context

Case counts cannot be interpreted meaningfully without understanding exposure. Section 5 therefore provides estimates of cumulative and interval exposure from clinical development and post-marketing use where available.

Exposure estimates may be imperfect. Prescription data, sales data, treatment duration assumptions, patient counts and study exposure each measure different things. The report should describe the method and limitations sufficiently to prevent false precision.

Signal Evaluation and Risk Evaluation

Section 15 provides the structured overview of signals that were new, ongoing or closed during the interval. Section 16 then goes further by evaluating signals and characterising identified and potential risks.

A signal is not automatically a risk, and closure of a signal does not necessarily mean the underlying clinical issue disappears. The report should explain the evidence, conclusion and consequences of each important evaluation.

Risk characterisation may include frequency, severity, outcome, risk factors, preventability, reversibility, affected populations and uncertainties. The depth should be proportionate to the risk's importance.

Benefit Evaluation

The benefit side of the PBRER is not a repetition of the efficacy section from the original marketing application. It should describe whether new information changes the current understanding of therapeutic benefit in authorised use.

Relevant information may include new clinical-study results, effectiveness data, changes in treatment practice, evidence in important subgroups, emerging limitations of efficacy or developments in the therapeutic landscape.

Where no new information materially changes benefit, the report can state this clearly rather than manufacturing artificial analysis.

Integrated Benefit-Risk Analysis

Section 18 is the intellectual centre of the report. It should integrate the important benefits and risks by authorised indication and explain whether the overall balance remains favourable.

A strong analysis considers:

• the clinical importance and magnitude of benefit;
• the seriousness and frequency of important risks;
• uncertainty around both benefit and risk estimates;
• the population in whom benefit and harm occur;
• preventability and manageability of risks;
• available alternative therapies; and
• whether new evidence changes clinical decision-making.

The analysis should be explicit about uncertainty. Benefit-risk evaluation is not a numerical subtraction unless a validated quantitative framework is appropriate to the specific decision.

Preparation, Governance and Quality

A PBRER draws information from pharmacovigilance operations, clinical development, epidemiology, regulatory affairs, literature surveillance, signal management, risk management and medical review. The central challenge is therefore integration.

A practical workflow usually includes:

• confirmation of scope, DLP and submission requirements;
• source-data collection and reconciliation;
• medical review of interval and cumulative safety information;
• signal and risk assessment;
• benefit evaluation;
• integrated benefit-risk discussion;
• quality control of data, references and internal consistency; and
• final governance review and submission.

These are operational practices rather than a legally prescribed company workflow. The regulatory test is whether the report is complete, scientifically coherent, accurate and submitted in accordance with the applicable requirements.

QPPV oversight

The QPPV should have sufficient oversight of periodic reporting to understand important new safety information, significant benefit-risk conclusions, major regulatory implications and compliance with PSUR obligations. This does not imply that the QPPV must personally author or sign every section unless an applicable company or authority procedure requires it.

Relationship With Other Pharmacovigilance Processes

The PBRER should be consistent with the wider pharmacovigilance system.

• Signal management provides evaluated safety questions and conclusions.
• RMPs describe important risks, missing information and planned pharmacovigilance/risk-minimisation activities.
• PASS may generate evidence used in risk characterisation.
• Product information reflects authorised safety and efficacy information.
• Regulatory actions provide context for changes made during the interval.

Disagreement between these sources may be legitimate if timing or purpose differs, but it should be explainable.

Potential Failure Modes

The following are illustrative failure modes, not published inspection findings.

Inspection and Regulatory Review Considerations

An inspector or assessor may examine whether:

• PSUR obligations and EURD schedules are correctly controlled;
• source data can be traced to the report;
• important signals and risks are evaluated consistently;
• exposure estimates are methodologically understandable;
• late-breaking information is handled appropriately;
• conclusions are aligned with proposed actions; and
• significant report conclusions reach the QPPV and relevant governance.

Key Takeaways

The PBRER is a periodic scientific evaluation of the evolving benefit-risk balance, not a cumulative adverse-event listing.

In the EU, the legal instrument is the PSUR, while the scientific architecture is derived from ICH E2C(R2) and implemented through GVP Module VII.

The report's logic progresses from new evidence to signals, risks, benefits, integrated benefit-risk and action. The quality of the report depends primarily on the strength of this reasoning and the traceability of the evidence supporting it.

References

1. International Council for Harmonisation. ICH E2C(R2): Periodic Benefit-Risk Evaluation Report (PBRER).
2. European Medicines Agency. GVP Module VII — Periodic safety update report (Rev. 1). EMA/816292/2011 Rev. 1.
3. European Medicines Agency. Periodic safety update reports (PSURs) — current procedural guidance, EURD and PSUSA information.
4. European Union. Directive 2001/83/EC, as amended.
5. European Union. Regulation (EC) No 726/2004, as amended.
6. European Union. Commission Implementing Regulation (EU) No 520/2012, consolidated version current at 12 February 2026.
7. European Medicines Agency. GVP Module VII explanatory note Rev. 4, updated May 2026.

Regulatory Note

This article distinguishes EU legal requirements, ICH scientific guidance, GVP implementation guidance and recommended operational practice. As of 8 September 2026, EMA continues to list GVP Module VII Rev. 1 as the published PSUR module; current EMA procedural advice was updated 13 July 2026. Future GVP revisions following Implementing Regulation (EU) 2025/1466 should be checked before a live submission.